All In Biotech

Drug Trial Radar · NCT05868226

PRE-ISPY Phase I/II Oncology Platform Program

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Feb 15, 2023

Primary completion

Dec 30, 2030

Study completion Dec 30, 2031

Sponsor

Lead sponsor
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ALX Oncology Inc.; Pfizer; Jazz Pharmaceuticals; TransCode Therapeutics
First posted
May 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/or a high risk of recurrence following prior treatment with curative intent. The overall goal is moving promising drug regimens into a larger phase II (or III) trial and in general could feed the neoadjuvant breast I-SPY 2 Trial (NCT01042379) and/or other oncology solid tumor trial in a timely manner.

Conditions

  • HER2-positive Breast Cancer
  • Metastatic Cancer
  • Metastatic Breast Cancer
  • Metastatic
  • HER2-positive Metastatic Breast Cancer
  • HER2 Mutation-Related Tumors
  • HER-2 Protein Overexpression
  • HER2-negative Breast Cancer
  • Triple Negative Breast Cancer
  • HR Positive
  • Hormone Receptor-positive Breast Cancer
  • Estrogen Receptor Positive Tumor
  • Progesterone Receptor-positive Breast Cancer
  • Hormone Receptor Negative Breast Carcinoma
  • Solid Tumor
  • Solid Tumor, Adult
  • Solid Carcinoma
  • HER2 Low Breast Cancer
  • HER2 Low Breast Carcinoma
  • ER Positive Breast Cancer
  • PR-positive Breast Cancer
  • Minimal Residual Disease
  • Colo-rectal Cancer
  • Colon Cancer
  • Rectal Cancer
  • ctDNA Monitoring
  • Colorectal Neoplasms
  • Colonic Neoplasms
  • Rectal Neoplasms
  • Neoplasm, Residual
  • Adenocarcinoma of Colon
  • Adenocarcinoma

Interventions

  • ALX148Drug

    Starting dose Dose Level 1 30mg/kg IV Q3W; Dose Level Minus 1 20 mg/kg IV Q3W (if needed); Dose Level 2 45 mg/kg IV Q3W;

  • Fam-Trastuzumab Deruxtecan-NxkiDrug

    5.4 mg/kg IV Q3W; allowed to dose reduce after DLT observation period

  • ZanidatamabDrug

    20 mg/kg IV Q2W on Day 1 and Day 15 of each 28 day cycle

  • TucatinibDrug

    Dose Level 1: 300 mg PO BID daily; Dose Leve Minus 1: 250 mg PO BID daily

  • TTX-MC138Drug

    4.8 mg/kg Q4W IV on Day 1 for up to 12 cycles as interception therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events related to the treatmentTime frame: Start of treatment to 30 days post treatment (estimated 12 -18 months)
  2. For Phase Ib Part 1 study design: Incidence of Dose Limiting Toxicities (DLTs) at each dose levelTime frame: DLT observation period: Start of treatment to end of Cycle 1
  3. For select drug arms, Maximum Tolerated Dose (MTD)Time frame: Start of treatment to the date of last participant at end of DLT observation period at highest dose level (estimated 6 months)
  4. For Phase Ib Part 1 drug arms, Recommended Phase 2 Dose (RP2D)Time frame: Start of treatment to the date of last participant at highest dose level (estimated 6 months)
  5. Overall Response Rate (ORR)Time frame: Start of treatment to 12 months
  6. Duration of Response (DOR)Time frame: Start of treatment to 12 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center

    Birmingham, Alabama · Recruiting

  • Mayo Clinic Comprehensive Cancer Center

    Phoenix, Arizona · Not yet recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Active not recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Active not recruiting

  • The University of Chicago Medicine Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital

    New Lenox, Illinois · Recruiting

  • UChicago Medicine Orland Park

    Orland Park, Illinois · Recruiting

  • University of Minnesota Masonic Cancer Center

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic Comprehensive Cancer Center

    Rochester, Minnesota · Not yet recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.